title: Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
abstract: The aim of the study was to compare our reference adjuvant chemotherapy, FEC100 (fluorouracil 500 mg m(-2), epirubicin 100 mg m(-2) and cyclophosphamide 500 mg m(-2), six cycles every 21 days), to an epirubicin-vinorelbine (Epi-Vnr) combination for early, poor-prognosis breast cancer patients. Patients (482) were randomised to receive FEC100, or Epi-Vnr (epirubicin 50 mg m(-2) day 1 and vinorelbine 25 mg m(-2), days 1 and 8, six cycles every 21 days). The 7-year disease-free survival rates were 59.4 and 58.8%, respectively (P=0.47). The relative dose intensity of planned epirubicin doses was 89.1% with FEC100 and 88.9% with Epi-Vnr. There were significantly more grades 3-4 neutropenia (P=0.009) with Epi-Vnr, and significantly more nausea-vomiting (P<0.0001), stomatitis (P=0.0007) and alopecia (P<0.0001) with FEC100. No cases of congestive heart failure were reported, whereas four decreases in left ventricular ejection fraction occurred after FEC100 and five after Epi-Vnr. One case of acute myeloblastic leukaemia was registered in the FEC100 arm. After 7 years of follow-up, there was no difference between treatment arms. Epi-Vnr regimen provided a good efficacy in such poor-prognosis breast cancer patients, and could be an alternative to FEC100, taking into account respective safety profiles of both regimens.
authors.affiliation: Department of Medical Oncology, Centre Eugène Marquis, Université de Rennes, Rue de la Bataille Flandres-Dunkerque, CS 44229, 35042 Rennes, France. kerbrat@rennes.fnclcc.fr
authors.forename: P
authors.initials: P
authors.lastname: Kerbrat
authors.forename: H
authors.initials: H
authors.lastname: Roché
authors.forename: J
authors.initials: J
authors.lastname: Bonneterre
authors.forename: C
authors.initials: C
authors.lastname: Veyret
authors.forename: A
authors.initials: A
authors.lastname: Lortholary
authors.forename: A
authors.initials: A
authors.lastname: Monnier
authors.forename: P
authors.initials: P
authors.lastname: Fumoleau
authors.forename: P
authors.initials: P
authors.lastname: Fargeot
authors.forename: M
authors.initials: M
authors.lastname: Namer
authors.forename: P
authors.initials: P
authors.lastname: Chollet
authors.forename: M-J
authors.initials: MJ
authors.lastname: Goudier
authors.forename: B
authors.initials: B
authors.lastname: Audhuy
authors.forename: H
authors.initials: H
authors.lastname: Simon
authors.forename: P
authors.initials: P
authors.lastname: Montcuquet
authors.forename: J-C
authors.initials: JC
authors.lastname: Eymard
authors.forename: S
authors.initials: S
authors.lastname: Walter
authors.forename: P
authors.initials: P
authors.lastname: Clavère
authors.forename: J-P
authors.initials: JP
authors.lastname: Guastalla
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D018450:Disease Progression; D015251:Epirubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D005602:France; D006801:Humans; D008207:Lymphatic Metastasis; D008408:Mastectomy; D008875:Middle Aged; D016019:Survival Analysis; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D015251:Epirubicin; D014747:Vinblastine; D003520:Cyclophosphamide; D000077235:Vinorelbine; D005472:Fluorouracil